Intellipharmaceutics International Inc. Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2013 to Q3 2023

Taxonomy & unit
us-gaap: CAD and USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Intellipharmaceutics International Inc. quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2013 to Q3 2023.
  • Intellipharmaceutics International Inc. Net Income (Loss) Attributable to Parent for the quarter ending August 31, 2023 was -$1.89M, a 548% decline year-over-year.
  • Intellipharmaceutics International Inc. Net Income (Loss) Attributable to Parent for the twelve months ending August 31, 2023 was -$3.18M, a 19.9% increase year-over-year.
  • Intellipharmaceutics International Inc. annual Net Income (Loss) Attributable to Parent for 2022 was -$2.89M, a 43.8% increase from 2021.
  • Intellipharmaceutics International Inc. annual Net Income (Loss) Attributable to Parent for 2021 was -$5.15M, a 51.7% decline from 2020.
  • Intellipharmaceutics International Inc. annual Net Income (Loss) Attributable to Parent for 2020 was -$3.39M, a 58.1% increase from 2019.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 -$3.18M -$1.89M -$1.6M -548% Jun 1, 2023 Aug 31, 2023 6-K 2023-10-16
Q2 2023 -$1.58M -$54.1K +$787K +93.6% Mar 1, 2023 May 31, 2023 6-K 2023-09-26
Q1 2023 -$2.37M -$356K +$525K +59.6% Dec 1, 2022 Feb 28, 2023 6-K 2023-09-26
Q4 2022 -$2.89M -$879K +$1.08M +55.1% Sep 1, 2022 Nov 30, 2022 20-F/A 2024-02-06
Q3 2022 -$3.97M -$292K +$973K +76.9% Jun 1, 2022 Aug 31, 2022 6-K 2023-10-16
Q2 2022 -$4.94M -$841K +$160K +16% Mar 1, 2022 May 31, 2022 6-K 2023-09-26
Q1 2022 -$5.1M -$881K +$43.6K +4.72% Dec 1, 2021 Feb 28, 2022 6-K 2023-09-26
Q4 2021 -$5.15M -$1.96M -$2.39M -553% Sep 1, 2021 Nov 30, 2021 20-F/A 2024-02-06
Q3 2021 -$2.76M -$1.26M -$237K -23.1% Jun 1, 2021 Aug 31, 2021 6-K 2021-10-15
Q2 2021 -$2.52M -$1M +$48.2K +4.6% Mar 1, 2021 May 31, 2021 6-K 2022-07-21
Q1 2021 -$2.57M -$925K +$823K +47.1% Dec 1, 2020 Feb 28, 2021 6-K 2022-04-14
Q4 2020 -$3.39M $432K +$1.76M Sep 1, 2020 Nov 30, 2020 20-F/A 2024-02-06
Q3 2020 -$5.16M -$1.03M +$427K +29.4% Jun 1, 2020 Aug 31, 2020 6-K 2021-10-15
Q2 2020 -$5.58M -$1.05M +$1.02M +49.4% Mar 1, 2020 May 31, 2020 6-K 2021-07-15
Q1 2020 -$6.61M -$1.75M +$1.48M +45.8% Dec 1, 2019 Feb 29, 2020 6-K 2021-04-14
Q4 2019 -$8.08M -$1.33M +$2.45M +64.8% Sep 1, 2019 Nov 30, 2019 20-F/A 2022-05-09
Q3 2019 -$10.5M -$1.45M +$2.5M +63.2% Jun 1, 2019 Aug 31, 2019 6-K 2020-10-15
Q2 2019 -$13M -$2.07M +$786K +27.5% Mar 1, 2019 May 31, 2019 6-K 2020-07-15
Q1 2019 -$13.8M -$3.22M -$74.9K -2.38% Dec 1, 2018 Feb 28, 2019 6-K 2020-05-29
Q4 2018 -$13.7M -$3.78M Sep 1, 2018 Nov 30, 2018 20-F 2021-03-31
Q3 2018 -$3.95M -$1.4M -55% Jun 1, 2018 Aug 31, 2018 6-K 2019-10-11
Q2 2018 -$2.86M -$1.05M -58.4% Mar 1, 2018 May 31, 2018 6-K 2019-07-10
Q1 2018 -$3.15M Dec 1, 2017 Feb 28, 2018 6-K 2019-04-15
Q3 2017 -$2.55M Jun 1, 2017 Aug 31, 2017 6-K 2018-10-15
Q2 2017 -$1.81M Mar 1, 2017 May 31, 2017 6-K/A 2018-07-24
Q1 2014 $2.2M +$3.54M Dec 1, 2013 Feb 28, 2014 6-K 2014-04-14
Q1 2013 -$1.34M Dec 1, 2012 Feb 28, 2013 6-K 2014-04-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.